ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF – Get Rating) hit a new 52-week high on Monday . The stock traded as high as $5.80 and last traded at $5.80, with a volume of 24 shares trading hands. The stock had previously closed at $5.80.
ProMIS Neurosciences Stock Performance
The company has a market capitalization of $2.50 billion, a PE ratio of -10.20 and a beta of 1.08. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 1.08. The company has a 50-day moving average price of $5.80 and a two-hundred day moving average price of $5.49.
ProMIS Neurosciences Company Profile
(Get Rating)
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (ARFXF)
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- After a $100 Haircut, is Catalent an Oversold Pharma Play?
- Is Tyson Foods Too Cheap To Ignore?
- Alphabet Stock Offers a Rare Buying Opportunity
- Walt Disney Stock is Set to Reset Expectations
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.